Scott Gottlieb: We'll know more about prevalence of new Covid strains in the US soon
"I think we're going to know in the next week what the prevalence is of B 117 in Florida and San Diego," Dr. Scott Gottlieb, member of the boards of Pfizer and biotech company Illumina and former FDA commissioner, told CNBC's "Squawk Box" Wednesday. "We're doing enough sequencing right now that we can get an adequate measure of what the percent prevalence is."
UP NEXT
UP NEXT
-
Jim Cramer: 12 stocks to beat big institutional investors at their own game
CNBC
-
3D printed homes come to market
CNBC
-
Dr. Peter Hotez on why some states are doing better with Covid
CNBC
-
Militia groups believed Trump was on their side, says terrorism expert
CNBC
-
GOP leaders clash over fmr. Pres. Trump speaking at CPAC
CNBC
-
The fight over minimum wage
CNBC
-
Former Cuomo aide accuses him of sexual harassment
CNBC
-
MP Materials CEO says there's a new 'gold rush' in rare earth minerals
CNBC
-
FDA finds J&J vaccine 'safe' and 'effective'
CNBC
-
Tiger Woods recovers from multiple leg injuries sustained in crash
CNBC
-
Cramer's lightning round: Buy Advanced Micro Devices
CNBC
-
Trash Inc. The Secret Life of Garbage
CNBC
-
Jim Cramer gets behind five new SPAC ideas
CNBC
-
Wall Street finishes up, GameStop soars
Reuters
-
Moderna CEO talks Covid vaccine for new South African variant
CNBC
-
Post-Market Wrap: February 24, 2021
CNBC
-
CNBC Tech Check Evening Edition: February 24, 2021
CNBC
-
ETF Edge, February 24, 2021
CNBC
-
The mechanics behind two of the most popular space-related ETFs
CNBC
-
Breaking down Nvidia's fourth-quarter results
CNBC
-
What Queen Cathie's moves in the ARK ETF mean for the individual stocks
CNBC
-
Tilray-Aphria merger will create the largest retail cannabis company in the world, says Aphria CEO
CNBC